This kit is only used for the in vitro qualitative detection of 2019-nCoV antigen from
human nasopharyngeal swab, nasal swab or oropharyngeal swab specimens.
This kit is suitable for the auxiliary diagnosis of COVID-19, the results are for clinical
reference only and cannot be used as the sole basis for diagnosis and exclusion
decision. The clinical diagnosis and treatment of patients should be considered in
combination with their symptoms/signs, medical history, other laboratory tests and
treatment responses.
Positive test result needs to be further confirmed, negative result does not preclude
2019-nCoV infection.
This kit is intended for use by qualified and trained clinical laboratory personnel
specifically instructed and trained in the techniques of in vitro diagnostic procedures.
TEST PRINCIPLE
The kit is immunochromatographic and uses double-antibody sandwich method to
detect 2019-nCoV N protein antigen. During detection, the treated specimens are
loaded into the sample wells of the test card. When the concentration of 2019-nCoV
antigen in specimen is higher than the minimum detection limit, the viral antigen will
form complexes with labeled antibodies first. Under chromatography, the complexes
move forward along the nitrocellulose membrane till captured by pre-coated
monoclonal antibody of 2019-nCoV in detection zone on nitrocellulose film (T) to
form a pink/purple reaction line on the detection zone, at this point the result is
positive; conversely, if there is no viral antigen or the concentration of antigen in
specimen is below the minimum detection limit, no pink/purple reaction line appears
in the detection zone, at this point the result is negative. Regardless of whether the
sample contains viral antigens or not, a pink/purple reaction line will appear in the
quality control zone (C), the pink/purple reaction line that appears in the quality
control zone (C) is the criterion for determining if the chromatography process is
normal.
